Neutral Alkyl Amines Chemicals; target of Rs 1690: Motilal Oswal

Moneycontrol • 1 day ago

Original source

Key Investment Pillars

  • Rising demand from the pharma segment, particularly peptides, alongside healthy demand from agrochemicals and rubber chemicals, is expected to drive growth momentum for AACL.
  • The company's focus on gaining market share in existing products and expanding its portfolio into new product categories is expected to support growth.
  • Operating leverage, driven by higher capacity utilization, is expected to improve margins.
  • The planned commercialization of a new product at the Kurkumbh facility and additional products in the R&D pipeline are expected to contribute to growth.

Thesis Validation Checklist

  • Over the next 12 months, investors should watch for signs of improving operating leverage, such as expanding EBITDA margins, and growth in revenue from the pharma segment.
  • An increase in exports, with a target of 25% of total revenue, would be a positive signal.
  • The company's ability to maintain a healthy balance sheet, with a focus on debt reduction and cash generation, will be important to monitor.
  • Any updates on the commercialization of new products and progress on the R&D pipeline will be key to validating the growth thesis.